Tag: Lord Mancroft

The below Parliamentary question was asked by Lord Mancroft on 2016-04-13.

To ask Her Majesty’s Government what is the breakdown of run rates assigned to each Operational Delivery Network for hepatitis C, broken down by hub and spoke.

Lord Prior of Brampton

Operational Delivery Networks (ODNs) lead organisations in collaboration with the local NHS England commissioning team are responsible for approving the organisations involved in the ODN. The ODN lead provider is responsible for working with its partners in determining how the patient numbers will be managed across its network. NHS England does not hold this information.

The below Parliamentary question was asked by Lord Mancroft on 2016-03-23.

To ask Her Majesty’s Government how many people diagnosed with hepatitis C are eligible for treatment under the National Institute for Health and Care Excellence guidance for new direct acting antiviral drugs.

Lord Prior of Brampton

Based on National Institute for Health and Care Excellence (NICE) modelling, NHS England has planned for 10,000 patients to be treated in 2016/17. No national registry exists for hepatitis C and as a result NICE estimates that the NHS should be treating 10,000 people based on the total number of people diagnosed with hepatitis C, their genotype, their treatment history and their disease severity, all of which impact on treatment eligibility.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-14.

To ask Her Majesty’s Government when NHS England expects to publish its operational framework for hepatitis C.

Lord Prior of Brampton

NHS England has already published its planning approach to implement National Institute for Health and Care Excellence (NICE) recommended treatment during 2016/17. NHS England has committed to produce an operational framework for hepatitis C during 2016/17. This will set out NHS England’s commitment to improving outcomes in hepatitis C across England. The publication date for the document has not been set but we anticipate work to continue during the late spring and early summer.

NICE Technology Appraisals (TA) 363, 364 and 365 require Operational Delivery Networks to prioritise treatment for patients with the highest unmet clinical need. The National Health Service commitment to 10,000 treatments in 2016/17 reflects the multi-year modelling used by NICE and published in conjunction with the recommendations for TA 364. The NICE recommendations note that treatment decisions are influenced by clinical characteristics such as level of liver damage, genotype, treatment history and comorbidities. The recommendations also record the advice of clinical experts to the committee that a realistic estimate of patients accessing treatment each year is between 7-10,000.

The below Parliamentary question was asked by Lord Mancroft on 2016-03-23.

To ask Her Majesty’s Government what plans they have to review their hepatitis C strategy in the light of other European countries’ strategies for tackling hepatitis C.

Lord Prior of Brampton

NHS England has been rapidly working on their plans for access to treatment during 2016/17 following enactment of the National Institute for Health and Care Excellence technical appraisal guidance and has committed to produce an operational framework for the treatment of hepatitis C during 2016/17. This will set out NHS England’s commitment to improving outcomes in hepatitis C across England.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-14.

To ask Her Majesty’s Government which current policy document or guidance, if any, specified a five-year rollout for the prioritised treatment of hepatitis C patients.

Lord Prior of Brampton

NHS England has already published its planning approach to implement National Institute for Health and Care Excellence (NICE) recommended treatment during 2016/17. NHS England has committed to produce an operational framework for hepatitis C during 2016/17. This will set out NHS England’s commitment to improving outcomes in hepatitis C across England. The publication date for the document has not been set but we anticipate work to continue during the late spring and early summer.

NICE Technology Appraisals (TA) 363, 364 and 365 require Operational Delivery Networks to prioritise treatment for patients with the highest unmet clinical need. The National Health Service commitment to 10,000 treatments in 2016/17 reflects the multi-year modelling used by NICE and published in conjunction with the recommendations for TA 364. The NICE recommendations note that treatment decisions are influenced by clinical characteristics such as level of liver damage, genotype, treatment history and comorbidities. The recommendations also record the advice of clinical experts to the committee that a realistic estimate of patients accessing treatment each year is between 7-10,000.

The below Parliamentary question was asked by Lord Mancroft on 2016-03-23.

To ask Her Majesty’s Government whether plans to introduce a hepatitis C improvement framework have been abandoned and, if so, why.

Lord Prior of Brampton

NHS England has been rapidly working on their plans for access to treatment during 2016/17 following enactment of the National Institute for Health and Care Excellence technical appraisal guidance and has committed to produce an operational framework for the treatment of hepatitis C during 2016/17. This will set out NHS England’s commitment to improving outcomes in hepatitis C across England.

The below Parliamentary question was asked by Lord Mancroft on 2016-04-14.

To ask Her Majesty’s Government what impact assessment they made of the introduction of CQUIN scheme BI1 Improving HCV Treatment Pathways through ODNs, and whether they will publish a copy of that assessment.

Lord Prior of Brampton

The National Institute for Health and Care Excellence specifically requires Operational Delivery Networks to prioritise hepatitis C patients on the basis of clinical need, as part of a progressive rollout of treatments over the next five years and the Commissioning for Quality and Innovation scheme (CQUIN) enables and ensures this take place. There is no separate assessment of impact. NHS England recognises that there is a very significant improvement in inequalities as a result of roll-out treatment for hepatitis C.